Trial
NCT00113802
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Waldenstrom Macroglobulinemia
Intervention
Epratuzumab (hLL2- anti-CD22 humanized antibody)
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19